ELTK Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
ELTK is not a good buy right now for a beginner long-term investor with $50,000-$100,000 available. The stock is in a weak technical position, the latest quarter showed revenue growth but sharply weaker profitability, and there is no bullish proprietary signal to override that. Given the current setup and the user's impatience, the better call is to avoid buying now.
ELTK's price is 8.02, below the previous close of 8.2425, with both pre-market and post-market weakness. The technical picture is bearish: MACD histogram is negative and expanding, RSI_6 at 31.994 is weak but not oversold enough to clearly signal a rebound, and moving averages are stacked bearishly with SMA_200 > SMA_20 > SMA_5. Price is also below the pivot at 8.49 and near support at 8.143 / 7.929, which means momentum remains fragile. The stock trend data also points lower over the next day, week, and month.
Revenue in Q4 2025 increased 23.05% year over year, showing top-line growth. The company also serves defense, aerospace, and medical markets, which can provide stable demand, and it is ITAR compliant with relevant certifications. Eltek also has a Q1 2026 earnings release scheduled, which could become a catalyst if results improve materially.
Recent market action is weak, with the stock closing lower and post-market pressure continuing. Profitability deteriorated sharply in Q4 2025, with net income turning negative and gross margin falling significantly. Hedge funds and insiders are both neutral, with no meaningful accumulation signal. No recent congress trading data is available, and there are no bullish AI Stock Picker or SwingMax signals today.
In Q4 2025, Eltek reported revenue of 13.238 million, up 23.05% year over year, which is a positive growth trend. However, the company posted a net loss of 310,000, down 1509.09% year over year, and gross margin fell to 8.74%, down 51.39% year over year. EPS was -0.05. Overall, sales improved but earnings quality and margin strength weakened materially in the latest quarter.
No analyst rating or price target change data was provided, so there is no clear Wall Street upgrade/downgrade trend to support a buy case. Based on the available data, Wall Street would likely see the main pro as revenue growth and the main con as weak profitability, falling margins, and bearish price action.
